THROMBOPHILIA MARKERS AT WOMEN PATIENTS WITH HISTORY OF FETO-MATERNAL DISEASE AND THROMBOPHILIA
https://doi.org/10.17749/2313-7347.2015.9.1.063-067
Abstract
The level of molecular markers of a thrombophilia (TAT, D-dimer) and platelet aggregate formation activity allows to estimate risk of obstetric complications at patients with the complicated pregnancy in the anamnesis and a thrombophilia. We observed 63 pregnant women (pregnancy term from 6 to 13 weeks) and 86 women planning pregnancy from which at 54 there was a preeclampsia in the anamnesis at 43 - a premature detachment of placenta, at 52 - antenatal fetal death. 53.0% patients with the complicated pregnancy in the anamnesis had high D-dimer; TAT - 55.0%; aggregation activity of platelets - 59.7%. High level of molecular markers of a thrombophilia are the indication to application the antithrombotic therapy and allow to control efficiency of this therapy
About the Author
M. D. Andreeva
Kuban State Medical University, Ministry of Health of Russia, Moscow
Russian Federation
the Chair of Obstetrics, Gynecology and Perinatolology
Russian Federation
the Chair of Obstetrics, Gynecology and Perinatolology
References
1. Thrombohemorrhagic complications in obstetric practice: A guide for physicians. Ed. AD Makatsaria [Trombogemorragicheskie oslozhneniya v akushersko-ginekologicheskoi praktike: Rukovodstvo dlya vrachei. Pod red. A.D. Makatsarii]. Moscow. 2011; 1056 s.
2. Samburova N.V. The clinical significance of monitoring blood coagulation activation markers during antithrombotic therapy in pregnancy, childbirth and postpartum women with thrombophilia Phd. Diss. [Klinicheskoe znachenie kontrolya markerov aktivatsii svertyvaniya krovi pri provedenii protivotromboticheskoi terapii u beremennykh, rozhenits i rodil'nits s trombofiliei: dis....kand. med. nauk]. Moscow. 2008; 132 s.
3. Kovac M., Mitic G. et al. Thrombophilia in women with pregnancy-associated complications: fetal loss and pregnancy-related venous thromboembolism. Gynecol. Obstet. Invest. 2010; 69 (4): 233-8.
4. Kupferminc M.J. Thrombophilia and pregnancy. Reprod. Biol. Endocrinol. 2003; 1: 111.
5. Lykke J.A., Bare L.A., Olsen J. et al. Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort. J. Thromb. Haemost. 2012; 10 (7): 1320-1325.
6. Rodger M.A. An update on thrombophilia and placenta mediated pregnancy complications: What should we tell our patients? Thromb. Res. 2013; 131 (1): 25-27.
7.
8.
Review
For citations:
Andreeva M.D. THROMBOPHILIA MARKERS AT WOMEN PATIENTS WITH HISTORY OF FETO-MATERNAL DISEASE AND THROMBOPHILIA. Obstetrics, Gynecology and Reproduction. 2015;9(1):63-67. (In Russ.) https://doi.org/10.17749/2313-7347.2015.9.1.063-067
Views:
591
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
